Although right‐sided colorectal cancer (CRC) shows a worse prognosis than left‐sided
CRC, the underlying mechanism remains unclear. We established patient‐derived …

Background The objective of this randomized phase II trial was to evaluate efficacy and
safety of the therapeutic sequence of regorafenib followed by cetuximab, compared with …

Abstract Background OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating
tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal …

Background Treatment with regorafenib, a multiple-kinase inhibitor, to manage metastatic
colorectal cancers (mCRCs) shows a modest improvement in overall survival but is …

Background: To investigate the cost–effectiveness of nivolumab versus chemotherapy in the
second-line treatment for advanced esophageal squamous cell carcinoma. Materials & …

Colorectal cancer (CRC) is the third most common malignant tumor and the second most
fatal cancer worldwide. Several parts of the immune system contribute to fighting cancer …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this
guide published by the Spanish Society of Medical Oncology is to develop a consensus for …

Summary This Expert Opinion article thoroughly analyses the Barcelona Clinic Liver Cancer
(BCLC) staging and treatment algorithm for hepatocellular carcinoma (HCC) that, since …

Background & Aims Tumor genetic testing is indispensable in the management of primary
and metastatic colorectal cancer (CRC), yet the indications for genomics-guided precision …